Physician profile
Jonathan B Lis
NPI 1528558939
$1,783.80
in general payments reported to CMS, 2019-2025
24 companies · $160 in 2025
The $160 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $164 · 2023: $677 · 2024: $782 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,513.44 |
| Education | $105.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $279.03 | 2023-2025 | |
| Glaxosmithkline, LLC. | $247.16 | 2022-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $212.91 | 2022-2024 | Breztri, Farxiga |
| Pfizer INC. | $127.41 | 2023-2024 | |
| Lilly USA, LLC | $81.16 | 2023-2024 | Mounjaro, Zepbound |
| Lundbeck LLC | $80.26 | 2023-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $79.90 | 2023-2024 | Rexulti, Jynarque |
| Exact Sciences Corporation | $76.22 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $72.97 | 2023-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $63.86 | 2022-2023 | |
| Dexcom, INC. | $49.29 | 2023-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $49.08 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $44.61 | 2024 | Gemtesa |
| Astellas Pharma US INC | $44.05 | 2024 | Veozah |
| Bausch Health US, LLC | $41.33 | 2022-2023 | Wellbutrin, Aplenzin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.50 | 2022-2023 | Xifaxan |
| Amgen INC. | $34.83 | 2023-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $29.87 | 2023 | Gattex |
| Eisai INC. | $25.34 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.38 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $21.16 | 2024 | Uzedy |
| Corium, LLC | $20.81 | 2023 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.02 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.65 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.